Genetic Determinants of Amitriptyline Efficiency for Pain Treatment - Part II
Status:
Completed
Trial end date:
2019-01-01
Target enrollment:
Participant gender:
Summary
Low dose tricyclic antidepressant drugs are routinely administered co-analgesics in pain
medicine. Amitriptyline is largely considered as a gold standard. Amitriptyline underlies
cytochrome CYP2D6 and CYP2D19 metabolism. CYP2D6 is highly polymorphic; numerous genetic
variants result in 4 major classes characterizing enzymatic activity: poor metabolizers,
intermediate metabolizers, extensive metabolizers and ultrarapid metabolizers. It is not
known to which extent metabolizer classes determine pain outcomes or side-effects. As only
one in three pain patients is considered to be a responder to amitriptyline's co-analgesic
effect, prediction of treatment efficacy with a fast and easy to perform bedside test may
contribute to the patients quality of life. The aim of this study is to determine the
influence of cytochrome variants on experimental pain, drug related side-effects and finally
identification of active metabolites.
Phase:
Phase 4
Details
Lead Sponsor:
University Hospital Inselspital, Berne
Collaborators:
Aalborg University Ludwig-Maximilians - University of Munich University of Washington
Treatments:
Amitriptyline Amitriptyline, perphenazine drug combination Tolterodine Tartrate